About Vanda Pharmaceuticals
Vanda Pharmaceuticals is a company based in Washington (United States) founded in 2003. Vanda Pharmaceuticals has raised $33.5 million across 2 funding rounds from investors including Domain Associates, Prospect Venture Partners and Rho Capital Partners. The company has 368 employees. Vanda Pharmaceuticals offers products and services including HETLIOZ®, Fanapt®, and Ponvory®. Vanda Pharmaceuticals operates in a competitive market with competitors including Alto Neuroscience, Newron Pharmaceuticals, Supernus Pharmaceuticals, Neurovance and Seaport Therapeutics, among others.
- Headquarter Washington, United States
- Employees 368
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website vandapharma.com
- Social LinkedIn X
- Legal Name Vanda Pharmaceuticals Inc.
- Annual Revenue$216.1 M (USD)8.72as on Dec 31, 2025
- Net Profit-$220.47 M (USD)-1066.53as on Dec 31, 2025
- EBITDA-$139.25 M (USD)-328.1as on Dec 31, 2025
- Total Equity Funding$33.5M (USD)
in 2 rounds
- Latest Funding Round$15M (USD), Series B
Dec 2005
- InvestorsDomain Associates
& 5 more
- Employee Count368
Products & Services of Vanda Pharmaceuticals
Vanda Pharmaceuticals offers a comprehensive portfolio of products and services, including HETLIOZ®, Fanapt®, and Ponvory®.
Medication for treating sleep-wake disorders and related conditions.
Antipsychotic treatment for schizophrenia and other mental health issues.
Therapy for relapsing forms of multiple sclerosis.
Funding Insights of Vanda Pharmaceuticals
Vanda Pharmaceuticals has successfully raised a total of $33.5M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in December 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $33.5M
- Total Rounds 2
- Last Round Series B — $15M
- First Round $18.5M
(Oct 2004)
- Investors Count 6
All 2 funding rounds of Vanda Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2005 | $15M | Series B | – | – | – |
| Oct 2004 | $18.5M | Series B | – | – |
6 investors in total: 6 institutional.
Investors in Vanda Pharmaceuticals
Vanda Pharmaceuticals has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Domain Associates, Prospect Venture Partners and Rho Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science & tech focused VC firm investing in the US | – | domainvc.com | Princeton, United States | |
Investments are made in US life sciences and healthtech firms. | – | prospectventures.com | Palo Alto, United States | |
Early-stage tech startups are invested in by Rho Capital Partners. | – | rho.com | New York, United States | |
- | – | medimmuneventures.com | - | |
- | – | carecapital.com | - | |
Government-backed investments are directed toward healthcare, fintech, and various sectors. | – | edbi.com | Singapore, Singapore |
Investor details for Vanda Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vanda Pharmaceuticals
131 people are tracked at Vanda Pharmaceuticals (33 in leadership, 5 in board & advisors, 93 in team); the tracked headcount is 368.
| Name | Role | Group |
|---|---|---|
Mihael H Polymeropoulos | CEO & President | Leadership |
Kevin Moran | SVP, Chief Financial Officer and Treasurer | Leadership |
James P. Kelly | Executive Vice President, CFO & Treasurer | Leadership |
Gunther Birznieks | Senior Vice President, Business Development | Leadership |
Aranthan Jones | Chief of Corporate Affairs and Communications Officer | Leadership |
Joakim Wijkstrom | Senior Vice President, Chief Marketing Officer | Leadership |
Sandra Paulina Smieszek | Head | Leadership |
Chris Scheible | Associate Director Of Finance | Leadership |
Scott Howell | Chief People Officer | Leadership |
Tim Williams | Senior Vice President, General Counsel & Secretary | Leadership |
Peter Reed | Vice President, Commercial (us And Global Access, Reimbursement And Trade) | Leadership |
Jesse L. Carlin | Director, Clinical Development | Leadership |
Mallery Mayo | Senior Director Of Medical Affairs | Leadership |
Tom Griffin | Vice President Of Sales Commercial | Leadership |
Shahed Mohammadi | Executive Director Of IT | Leadership |
Chris Hanson | Senior Regional Sales Director | Leadership |
David Caron | Executive Director, Finance | Leadership |
Graziele M. | Head Of Payroll | Leadership |
Mudasir Rizvi | Executive Director Finance | Leadership |
Nicole Ziolkowski | Director, Finance | Leadership |
111 more people are available in the full profile.
Complete people profiles for Vanda Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Vanda Pharmaceuticals
Vanda Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol VNDA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Apr 2006
- Listed onNASDAQ: VNDA
- Listed entityVanda Pharmaceuticals Inc.
- Exchange sectorHealth technology
- ISINUS9216591084
- Share price$4.57 (+0.88% on the day) · 2026-10-09
- Market capitalisation$276.3M
- EPS (diluted, trailing year)$-4.63
- Volume (last session)640,258
Financials of Vanda Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $216.1M | -$220.5M | -$139.2M |
| 2024 | $198.8M | -$18.9M | -$32.5M |
| 2023 | $192.6M | $2.5M | -$10.9M |
| 2022 | $254.4M | $6.3M | $9.1M |
| 2021 | $268.7M | $33.1M | $45.0M |
Detailed financial statements for Vanda Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Vanda Pharmaceuticals
4 dated milestones of Vanda Pharmaceuticals across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Vanda Pharmaceuticals is founded.
- Funding First funding round of $18.5M.
- Funding Latest funding round, Series B, of $15.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Vanda Pharmaceuticals
Vanda Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Newron Pharmaceuticals, Supernus Pharmaceuticals, Neurovance and Seaport Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| newron.com | 1999 | Milan, Italy | $54.94M | – | Therapies for central nervous system diseases and pain are developed. | |
| supernus.com | 2005 | Rockville, United States | – | 652 | Specialty pharmaceutical products for CNS diseases are developed and commercialized. | |
| neurovance.com | 2011 | Cambridge, United States | $53.03M | 7 | Neurochemical modulators for ADHD treatment are developed by Neurovance. | |
| seaporttx.com | 2020 | Boston, United States | $325M | – | Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology. | |
| pasithea.com | 2020 | Miami Beach, United States | $1.46M | 15 | Pasithea is focused on developing treatments for neurological disorders. | |
| synchroneuron.com | 2006 | Newton, United States | $26M | – | Improved acamprosate formulations are developed for neuropsychiatric disorders. | |
| naurex.com | 2008 | Evanston, United States | $162.11M | – | Novel therapies for depression and CNS disorders are developed clinically. | |
| cadenttx.com | 2010 | Cambridge, United States | $63.73M | 13 | Precision medicines for neurological diseases are developed by Cadent Therapeutics. | |
| reunionneuro.com | 2022 | Toronto, Canada | $103M | – | Therapeutics for mental health conditions are developed using serotonergic psychedelics. |
Detailed competitors of Vanda Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vanda Pharmaceuticals
The website of Vanda Pharmaceuticals (vandapharma.com) receives about 44.7K visits a month and ranks #942,850 among all websites worldwide, #1,145 in Biotechnology and Pharmaceuticals.
- Monthly visits44.7K
▲ 68.5% vs previous month
- Unique visitors12.2K
per month
- Global rank#942,850
among all websites
- Category rank#1,145
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit3.1
- Average visit2 min 16 sec
- DevicesDesktop 60% · Mobile 40%
Websites whose visitors overlap most with Vanda Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
ir.momentapharma.com | ir.momentapharma.com | 100% | – | – | – |
| quarkpharma.com | 98% | – | – | View details | |
| biospecifics.com | 97% | – | – | View details | |
| lipa.com.au | 97% | 6.5K | #2,944,886 | View details | |
| deciphera.com | 97% | 12.2K | #2,044,202 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Vanda Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Vanda Pharmaceuticals
Complete news archive for Vanda Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Vanda Pharmaceuticals
10 companies that operate in the same segment as Vanda Pharmaceuticals (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Vanda Pharmaceuticals
Vanda Pharmaceuticals was founded in 2003 and raised its 1st funding round 1 year after it was founded.
Vanda Pharmaceuticals is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.
Mihael H Polymeropoulos is the current CEO of Vanda Pharmaceuticals.
Vanda Pharmaceuticals is a funded company, having raised a total of $33.5M across 2 funding rounds to date. The company's 1st funding round was a Series B of $18.5M, raised on Oct 2004.
Vanda Pharmaceuticals has 368 employees.
Annual revenue of Vanda Pharmaceuticals is $216.1M as on Dec 31, 2025.
Vanda Pharmaceuticals was founded in 2003 as a biopharmaceutical company. Focus is placed on the development and commercialization of treatments for central nervous system disorders. Two products, Fanapt and Hetlioza melatonin receptor agonisthave been approved. The pipeline features tradipitant in phase 2 trials for pruritus, along with Hetlioz in phase 3 for jet lag disorder, Smith-Magenis syndrome, and additional indications. Operations center on pharmaceutical innovation without specified geographic details.
Vanda Pharmaceuticals's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Vanda Pharmaceuticals offers HETLIOZ®, Fanapt®, and Ponvory®.
Yes, Vanda Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol VNDA.
Vanda Pharmaceuticals has 6 investors. Key investors include Domain Associates, Prospect Venture Partners, Rho Capital Partners, MedImmune Ventures, and Care Capital.
Vanda Pharmaceuticals operates through Vanda Pharmaceuticals Inc..